Traduction de «thromboembolism in women using » (Néerlandais → Français) :

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing

Lip GYH, Nieuwlaat R, Pisters R et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation.
predict warfarin-associated hemorrhage. The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.

(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral contraceptives
(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral

compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ
drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States

(Van Houdenhoven 2006) Van Houdenhoven K, van Kaam KJ, van Grootheest AC, Salemans TH, et al. Uterine perforation in women using a
(Van Houdenhoven 2006) Van Houdenhoven K, van Kaam KJ, van Grootheest AC, Salemans TH, et al. Uterine perforation in

Use of combined oral contraceptives among women with migraine and
Use of combined oral contraceptives among women with

In August, “The New England Journal of Medicine” published results from the landmark BIG 1-98 study affirming the five-year upfront use of Femara after surgery was an optimal treatment approach versus tamoxifen for postmenopausal women with early-stage, hormone-receptor positive breast cancer.
En août, «The New England Journal of Medicine» a publié les résultats de l’étude pivot BIG 1-98 qui démontrent que l’utilisation de Femara pendant cinq ans après l'intervention chirurgicale constituait une approche optimale par rapport au tamoxifène chez les femmes ménopausées atteintes d’un cancer du sein hormonodépendant précoce.

US and European regulatory submissions are planned in the 2009 fourth quarter for the use of Zometa in adjuvant breast cancer in premenopausal women based on published anti-cancer data for this indication.
Des demandes d’autorisation aux Etats-Unis et en Europe sont prévues au quatrième trimestre 2009 pour l’utilisation de Zometa en tant qu’adjuvant dans le traitement du cancer du sein chez les femmes préménopausées sur la base des données anticancer publiées pour cette indication.

Moreover, they use more “violent” means of committing suicide than women.
Ils ont, de plus, recours à des moyens plus « violents » de se donner la mort que les femmes.

Naar D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.
D’après D.M. Grabrick et al.: Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer.